Compare KraneShares CSI China Internet ETF (KWEB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Tango Therapeutics Inc. — how do they compare? KraneShares CSI China Internet ETF trades at $24.21 (market cap $4.50B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: KraneShares CSI China Internet ETF is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 59 Days and Tango Therapeutics Inc. for 0 Days on average.
| KWEB | TNGX | |
|---|---|---|
Market Cap | $4.50B | $3.74B |
Volume | 13,386,499 | 3,438,781 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $32.90 |
52-Week Low | $23.63 | $7.50 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.72, down slightly by 0.12% on the day, with technical indicators showing a neutral to bearish bias. The ETF faces mixed sentiment amid ongoing U.S.-China trade dynamics and institutional positioning shifts. Recent news highlights China's economic challenges, including industrial overcapacity and trade tensions, which impact the fund's holdings in Chinese internet companies.
The outlook remains cautious due to geopolitical risks and economic headwinds in China. While corporate profits showed strength in Q2 2026, weak domestic consumption and global trade friction pose significant risks. Institutional activity is mixed, with some firms reducing stakes, reflecting uncertainty about near-term performance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
